Tremelimumab and Imfinzi Combo Effective for Mesothelioma
The novel immunotherapy drug mixture of tremelimumab and Imfinzi (durvalumab) produced encouraging results in the first phase II mesothelioma clinical trial examining this combination. The study, which included 40 mesothelioma patients in Italy, was published in the June 2018 edition of The Lancet Respiratory Medicine. Similar — or even more promising — results with this combination are expected to follow soon in the United States. “Results from this study are very promising,” investigator Dr. Luana Calabro, Siena University Hospital, told Asbestos.com. “This regimen also has shown a good safe...
Source: Asbestos and Mesothelioma News - June 20, 2018 Category: Environmental Health Authors: Matt Mauney Source Type: news

‘Supercharged’ Immunotherapy Could Target Mesothelioma Cell Protein
Standard mesothelioma treatment options include surgery, radiation therapy, chemotherapy and multimodal therapy. These standard therapies do not offer a cure for people with mesothelioma, and that’s why scientists continue searching for better ways to treat the disease. Researchers at the Scripps Research Institute in Jupiter, Florida, have created a precision medicine approach that targets a protein on the surface of cancer cells to kill tumors. Although the drug was not specifically designed for mesothelioma patients, it may offer a more effective way to manage the disease in the future. The treatment is a type of...
Source: Asbestos and Mesothelioma News - June 18, 2018 Category: Environmental Health Authors: Matt Mauney Source Type: news

Results of Novel Mesothelioma Drug Presented at ASCO Meeting
A multicenter phase II clinical trial involving the latest orally administered protein inhibitor drug has shown considerable promise in helping control malignant mesothelioma. The effectiveness of tazemetostat was presented last week at the American Society of Clinical Oncology (ASCO) annual meeting in Chicago. The trial study, which will conclude late 2018, involves 74 previously treated patients with recurring mesothelioma. “We’ve seen benefit for some patients with this treatment and patients who have benefited over a long period of time,” medical oncologist Dr. Marianna Koczywas, City of Hope Cancer T...
Source: Asbestos and Mesothelioma News - June 14, 2018 Category: Environmental Health Authors: Matt Mauney Source Type: news

Nintedanib ‘ Superior ’ to Bevacizumab for Mesothelioma Treatment
Researchers in Austria, Germany and Hungary have added to the growing belief that the anti-cancer drug nintedanib may soon become a significant part of standard-of-care treatment for malignant pleural mesothelioma. In their study published recently in Clinical Cancer Research, nintedanib demonstrated an ability to inhibit the growth and the migration of mesothelioma tumor cells effectively in animal models. “This is a step in the right direction, another part of the evolutionary process of treatment advancements with this difficult disease,” Dr. Balazs Hegedus, department of thoracic surgery, University of Dui...
Source: Asbestos and Mesothelioma News - June 11, 2018 Category: Environmental Health Authors: Matt Mauney Source Type: news

In Missouri, J & J Faces Biggest Trial Yet Alleging Talc Caused Cancer In Missouri, J & J Faces Biggest Trial Yet Alleging Talc Caused Cancer
A lawsuit by 22 ovarian cancer patients against Johnson& Johnson went to trial on Wednesday in Missouri state court, marking the largest case the company has faced over allegations its talc-based products contain cancer-causing asbestos.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 8, 2018 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Johnson & Johnson defends talc products in latest court proceeding
Johnson& Johnson is being sued by a group of 22 ovarian cancer patients. The New Brunswick, New Jersey-based company (NYS: JNJ) faces charges that its talc-based products contain asbestos. The trial was brought forward by women who contend that J&J-branded baby powder contained the cancer-causing substance dating back at least to the 1970s. They also contend that J&J knew its talc was contaminated but failed to warn consumers about the risks. J&J has denied the assertions and maintains that its … (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - June 8, 2018 Category: American Health Authors: Anthony Noto Source Type: news

Johnson & Johnson defends talc products in latest court proceeding
Johnson& Johnson is being sued by a group of 22 ovarian cancer patients. The New Brunswick, New Jersey-based company (NYS: JNJ) faces charges that its talc-based products contain asbestos. The trial was brought forward by women who contend that J&J-branded baby powder contained the cancer-causing substance dating back at least to the 1970s. They also contend that J&J knew its talc was contaminated but failed to warn consumers about the risks. J&J has denied the assertions and maintains that its … (Source: bizjournals.com Health Care News Headlines)
Source: bizjournals.com Health Care News Headlines - June 7, 2018 Category: Health Management Authors: Anthony Noto Source Type: news

In Missouri, J & J faces biggest trial yet alleging talc caused cancer
NEW YORK (Reuters) - A lawsuit by 22 ovarian cancer patients against Johnson& Johnson went to trial on Wednesday in Missouri state court, marking the largest case the company has faced over allegations its talc-based products contain cancer-causing asbestos. (Source: Reuters: Health)
Source: Reuters: Health - June 6, 2018 Category: Consumer Health News Tags: healthNews Source Type: news

‘Right to Try Act’ Could Aid Mesothelioma Patients
Patients with mesothelioma may soon find an easier path to experimental drugs and treatments after President Donald Trump signed the “Right to Try Act” into law last week. The new legislation will give terminally ill patients a more direct and quicker line to drugs still awaiting approval from the U.S. Food and Drug Administration (FDA), bypassing the often-cumbersome application process. The law also will protect doctors and pharmaceutical companies from the legal risks of allowing unapproved treatments. The bill was passed by the Senate in August 2017 and cleared the House of Representatives late last month....
Source: Asbestos and Mesothelioma News - June 6, 2018 Category: Environmental Health Authors: Matt Mauney Source Type: news

Art Imitates Life:'Billions' Describes Six-Figure, Part-Time Jobs On Asbestos Trusts
Trustees, like the father of " Billions " co-creator Brian Koppelman, can make substantial salaries for part-time jobs doling out funds to asbestos claimants. (Source: Forbes.com Healthcare News)
Source: Forbes.com Healthcare News - June 6, 2018 Category: Pharmaceuticals Authors: Legal Newsline, Contributor Source Type: news

EPA Releases New Rules for TSCA Asbestos Review
As part of the latest updates to the reformed Toxic Substances Control Act (TSCA), the U.S. Environmental Protection Agency (EPA) last week proposed new rules for the risk evaluation of asbestos. The EPA released a significant new use rule (SNUR) proposal which would allow the agency to prevent new uses of asbestos, the naturally occurring mineral linked to deadly cancers such as mesothelioma. It is the first time the EPA has issued such an action. The SNUR would require the agency’s approval before asbestos-containing goods can be manufactured, imported or processed. It would grant the EPA power to evaluate the inte...
Source: Asbestos and Mesothelioma News - June 5, 2018 Category: Environmental Health Authors: Daniel King Source Type: news

Could Mesothelioma Chemotherapy Ever Be Obsolete?
Oncologist Dr. Arek Dudek at Regions Hospital Cancer Care Center in St. Paul, Minnesota, believes his clinical trial involving a novel immunotherapy combination could change the way doctors treat pleural mesothelioma. Dudek is opening the only Phase II trial evaluating the combination of nivalumab (Opdivo) and ramucirumab (Cyramza) for previously treated mesothelioma patients. “This strategy – if successful, like we think it will be – could make treatment with chemotherapy obsolete,” Dudek told Asbestos.com. “People can be really excited about this one.” He based his optimism on the pote...
Source: Asbestos and Mesothelioma News - June 1, 2018 Category: Environmental Health Authors: Walter Pacheco Source Type: news

Survey: Most Oncologists Discuss Medical Marijuana with Cancer Patients
Medical marijuana continues to be a hot topic among mesothelioma patients and a popular way to cope with disease symptoms and treatment side effects. As more states legalize marijuana for medicinal purposes, more cancer patients are asking their doctors about the natural therapy. A recent survey published in the Journal of Clinical Oncology shows as many as 80 percent of oncologists talk about medical marijuana with their patients. Of the 237 oncologists who responded to the survey, more than half (55 percent) practice in one of the 28 states where medical marijuana is legal. Questions on the survey covered recommendations...
Source: Asbestos and Mesothelioma News - June 1, 2018 Category: Environmental Health Authors: Daniel King Source Type: news

Three Weeks After Sheldon Silver Conviction, NY Lawmakers Balking At Asbestos Reform
More than a dozen states have enacted laws targeting the asbestos compensation system, but New York - home to one of the country's most notorious asbestos courts - has not. (Source: Forbes.com Healthcare News)
Source: Forbes.com Healthcare News - June 1, 2018 Category: Pharmaceuticals Authors: Legal Newsline, Contributor Source Type: news

Facility Expertise Matters for Mesothelioma Surgery
Patients having aggressive surgery for pleural mesothelioma at high-volume facilities experience fewer complications, shorter hospital stays and lower 30-day readmission rates than those treated at low-volume centers. Overall survival rates were higher and 90-day mortality rates were lower at the high-volume facilities, according to a study published in the June issue of Lung Cancer. The new study, based on data from the National Cancer Database (NCDB), is the largest to compare facility volume with post-surgery outcome for pleural mesothelioma. “In general, going to a high-volume center for oncology care makes sens...
Source: Asbestos and Mesothelioma News - May 30, 2018 Category: Environmental Health Authors: Matt Mauney Source Type: news

South Carolina J & J Baby Powder-Mesothelioma Case Ends in Mistrial
A South Carolina judge declared a mistrial Friday in a high-stakes case blaming asbestos-contaminated Johnson & Johnson Baby Powder for a woman’s mesothelioma. Jurors failed to reach a unanimous decision in the case of Bertila Boyd-Bostic, who was diagnosed with pericardial mesothelioma at the age of 30 and died 15 months later. Bostic’s husband, Antoine Bostic, sued Johnson & Johnson, talc supplier Imerys Talc America and drug store chain Rite Aid, alleging his wife’s death was caused by years of asbestos exposure from inhaling J&J baby powder. The 12-member jury could only reach a unanimous ...
Source: Asbestos and Mesothelioma News - May 29, 2018 Category: Environmental Health Authors: Daniel King Source Type: news

U.S. jury fails to reach verdict in latest J & J talc trial
NEW YORK (Reuters) - A South Carolina jury on Friday could not agree on a verdict in a case of a woman whose family said her long-term use of Johnson& Johnson's Baby Powder led to her death from asbestos-related cancer, resulting in a mistrial. (Source: Reuters: Health)
Source: Reuters: Health - May 25, 2018 Category: Consumer Health News Tags: healthNews Source Type: news

U.S. jury fails to reach verdict in latest Johnson & Johnson talc trial over asbestos claims
NEW YORK (Reuters) - A South Carolina jury on Friday could not agree on a verdict in a case of a woman whose family said her long-term use of Johnson& Johnson's Baby Powder led to her death from asbestos-related cancer, resulting in a mistrial. (Source: Reuters: Health)
Source: Reuters: Health - May 25, 2018 Category: Consumer Health News Tags: healthNews Source Type: news

J & J Must Pay $4 Mln in Punitive Damages in Asbestos Cancer Trial J & J Must Pay $4 Mln in Punitive Damages in Asbestos Cancer Trial
A California jury on Thursday ordered Johnson& Johnson to pay $4 million in punitive damages to a woman who said she developed cancer after being exposed to asbestos in the company's baby powder, pushing the total damages award in the case to $25.7 million.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - May 25, 2018 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Mother-of-two wins $25 million from Johnson & Johnson in talcum powder case
A California jury has ordered Johnson and Johnson to pay another $4 million to an Oregon mother-of-two who says that asbestos in the company's baby powder gave her mesothelioma. (Source: the Mail online | Health)
Source: the Mail online | Health - May 25, 2018 Category: Consumer Health News Source Type: news

Mother-of-two wins $4 million from Johnson & Johnson in talcum powder case
A California jury has ordered Johnson and Johnson to pay another $4 million to an Oregon mother-of-two who says that asbestos in the company's baby powder gave her mesothelioma. (Source: the Mail online | Health)
Source: the Mail online | Health - May 25, 2018 Category: Consumer Health News Source Type: news

Johnson & Johnson hit with $25.75 million verdict in talc-asbestos case
A California jury hit Johnson& Johnson and other companies with a $25.75 million verdict, saying the company was negligent and did not warn consumers about possible health risks from its Baby Powder. (Source: CNN.com - Health)
Source: CNN.com - Health - May 24, 2018 Category: Consumer Health News Source Type: news

J & J must pay $4 million in punitive damages in latest asbestos cancer trial
(Reuters) - A California jury on Thursday ordered Johnson& Johnson to pay $4 million in punitive damages to a woman who said she developed cancer after being exposed to asbestos in the company's baby powder, pushing the total damages award in the case to $25.7 million. (Source: Reuters: Health)
Source: Reuters: Health - May 24, 2018 Category: Consumer Health News Tags: healthNews Source Type: news

J & J Loses Second Asbestos in Talcum Powder Lawsuit
Johnson & Johnson suffered its second trial loss in two months Wednesday linking the company’s baby powder to deadly asbestos-related cancer. A Los Angeles jury awarded $21.7 million in compensatory damages to Joanne Anderson, who said she developed mesothelioma after being exposed to asbestos in J&J baby powder laced with the carcinogen. J&J was ordered to pay an additional $4 million in punitive damages Thursday, bringing the total award for Anderson to $25.7 million. The verdict comes less than two months after Johnson & Johnson’s first loss in an asbestos-related talcum powder lawsuit. In ...
Source: Asbestos and Mesothelioma News - May 24, 2018 Category: Environmental Health Authors: Matt Mauney Source Type: news

Novel Mesothelioma Treatment Uses Electrical Fields
Oncologists in 2019 may begin offering patients with pleural mesothelioma a novel, tumor-fighting tool involving electric currents that enhance standard-of-care treatment and extend survival, according to the device manufacturer. Tumor Treating Fields (TTF) is the name of the new technology. It is designed to disrupt cancer cell division through electric fields tuned to specific frequencies. In an ongoing multicenter phase II clinical trial in Europe, TTF has shown an ability in first-line treatment to improve the effectiveness of standard chemotherapy for mesothelioma patients. The trial success has led the manufacturer t...
Source: Asbestos and Mesothelioma News - May 24, 2018 Category: Environmental Health Authors: Matt Mauney Source Type: news

J & J hit with $21.7 million verdict in another talc asbestos cancer case
NEW YORK (Reuters) - Johnson& Johnson and its talc suppliers on Wednesday were hit with a $21.7 million jury verdict in a lawsuit by a woman who said she developed cancer after being exposed to asbestos in the company's Baby Powder. (Source: Reuters: Health)
Source: Reuters: Health - May 23, 2018 Category: Consumer Health News Tags: healthNews Source Type: news

Experts Discuss Unique Side Effects of Immunotherapy
If you have mesothelioma and you’ve already received standard-of-care therapies, you may be considering an immunotherapy clinical trial. If you’re considering this option, a free immunotherapy teleconference is a great place to learn more. CancerCare recently hosted two one-hour education workshops featuring panels of immunotherapy experts. Part I of the teleconference presented an overview of immunotherapy. Part II of the teleconference, which is available online for free, focused exclusively on immunotherapy side effects. Understanding these issues and the role each patient plays in managing their own side ef...
Source: Asbestos and Mesothelioma News - May 21, 2018 Category: Environmental Health Authors: Matt Mauney Source Type: news

Why is asbestos still killing people? – Science Weekly podcast
Every year, more people die from asbestos exposure than road traffic accidents in Great Britain. Many countries still continue to build with this lethal substance – but why?Hannah Devlin investigatesSubscribe and review onAcast,Apple Podcasts,Soundcloud,Audioboom andMixcloud. Join the discussion onFacebook andTwitterThe health effects of asbestos have been well documented for decades. Inhaling these fibres can cause mesothelioma, a very aggressive form of cancer with a poor prognosis. In Great Britain, more people die from this disease every year than road traffic accidents. And yet this material is still found in at...
Source: Guardian Unlimited Science - May 18, 2018 Category: Science Authors: Presented by Hannah Devlin and produced by Graihagh Jackson Tags: Science Health Medicine Cancer research Medical research Society Source Type: news

ONCOS-102 Mesothelioma Trial Moves Forward
Oncologists in Spain are recruiting patients for the randomized phase of the pleural mesothelioma clinical trial involving ONCOS-102, the promising immunotherapy vaccine. Optimism surrounding the trial stems from encouraging results obtained recently in the six-patient safety cohort used as a precautionary lead-in. The trial involves the vaccine in combination with standard-of-care chemotherapy for patients with inoperable disease. ONCOS-102 is a scientifically engineered adenovirus that is designed to activate a patient’s immune system to selectively target cancer cells. It is being developed by Targovax, a Scandina...
Source: Asbestos and Mesothelioma News - May 17, 2018 Category: Environmental Health Authors: Daniel King Source Type: news

Study Evaluates Systemic Chemotherapy on Peritoneal Mesothelioma
Systemic chemotherapy, either before or after cytoreductive surgery, provided no improvement in long-term survival for patients with peritoneal mesothelioma, according to a recent study. The addition of systemic chemotherapy improved survival at the one-year mark, but there were no benefits at the two-, three- or five-year checkpoints. Systemic chemotherapy uses anti-cancer drugs that are injected into a vein or given by mouth. The median survival of surgical patients who received systemic chemotherapy did not improve, either. “We know surgery is the best option, and if the surgery is successful, chemotherapy may not...
Source: Asbestos and Mesothelioma News - May 15, 2018 Category: Environmental Health Authors: Daniel King Source Type: news

J & J defends itself in trial over baby powder asbestos claims
(Reuters) - A trial for a lawsuit alleging that Johnson& Johnson Baby Powder was responsible for the death of a woman due to her exposure to cancer-causing asbestos began in South Carolina on Monday in the latest case against the healthcare conglomerate and a supplier over their talc-based products. (Source: Reuters: Health)
Source: Reuters: Health - May 14, 2018 Category: Consumer Health News Tags: healthNews Source Type: news

Study Reveals Emotional Needs of People Exposed to Asbestos
There is very little information available on the psychological care needs of people with malignant mesothelioma. Even less is known about people who have been exposed to asbestos but do not have mesothelioma. A newly published systematic research review sheds light on the distress people experience in these situations. In March 2018, the American Journal of Industrial Medicine published an article highlighting the need for additional studies. Researchers described what is known about asbestos-affected people and how and why they experience so much mental and emotional distress. Most Affected People Exposed Through Work Th...
Source: Asbestos and Mesothelioma News - May 14, 2018 Category: Environmental Health Authors: Matt Mauney Source Type: news

60 Minutes to speak to Boston Scientific in coverage of pelvic mesh MDL
CBS’s 60 Minutes will speak to Boston Scientific (NYSE:BSX) this week as the news program covers the massive multi-district litigation over gynecological pelvic mesh implants. The program referred to the multi-district litigation over the implants as the largest such litigation since asbestos, according to a press release. In early 2016, the FDA reclassified surgical meshes to treat pelvic organ prolapse in women as a Class III device, moving it up from a Class II classification. Research has indicated that meshes used transvaginal procedures to treat pelvic organ prolapse can lead to complications including mes...
Source: Mass Device - May 11, 2018 Category: Medical Devices Authors: Fink Densford Tags: Business/Financial News Legal News Women's Health Boston Scientific Pelvic Mesh Lawsuits Source Type: news

Peritoneal Mesothelioma Specialist Takes Expertise to South Florida
Dr. Shanel Bhagwandin saw the steady flow of patients who traveled from Southeast Florida to New York’s renowned Mount Sinai Hospital for the specialized treatment of peritoneal mesothelioma cancer. He knew there was a better way, and he just made it happen. Bhagwandin made the 1,200-mile move himself — from Mount Sinai to the Jupiter Medical Center — to start the latest surgical oncology program that specializes in cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC). “This procedure can make a tremendous difference,” Bhagwandin told Asbestos.com. “And it makes a ...
Source: Asbestos and Mesothelioma News - May 10, 2018 Category: Environmental Health Authors: Daniel King Source Type: news

NYC Asbestos Firm Hopes To Continue $117M Hot Streak, Again Seeking Punitives From J & J
Levy Konigsberg is apparently the first law firm in decades to seek punitive damages in an NYC asbestos case, while a possible appeal by defendants would decide whether it can. (Source: Forbes.com Healthcare News)
Source: Forbes.com Healthcare News - May 8, 2018 Category: Pharmaceuticals Authors: Legal Newsline, Contributor Source Type: news

Study: Open-Label Placebos Relieve Fatigue in Cancer Patients
It is common for cancer patients to experience fatigue during and after cancer treatment. Fatigue usually lessens as patients recover, but some patients experience long-term fatigue that gets in the way of the things they want to do. Mesothelioma survivors are among the many cancer patients who cope with fatigue once treatment ends. New research conducted by scientists at the University of Alabama at Birmingham and Harvard Medical School shows cancer-related fatigue can be relieved by a placebo pill. This relief even occurs when patients are aware they are taking a placebo, known as open-label placebo. A placebo is anythin...
Source: Asbestos and Mesothelioma News - May 7, 2018 Category: Environmental Health Authors: Daniel King Source Type: news

South Africa:Hope for Mafefe Residents As Asbestos Road Is Replaced
[News24Wire] In the hope that it would bring an end to the amount of deadly asbestos dust on their streets, residents of former asbestos-mining community Mafefe, have welcomed the construction of part of a road in the town at the cost of R43m. (Source: AllAfrica News: Health and Medicine)
Source: AllAfrica News: Health and Medicine - May 3, 2018 Category: African Health Source Type: news

Appeal Likely To Decide Future Of NYC Asbestos Court; Defendants Fed Up With Their Treatment
The fight over New York City ’s controversial asbestos court is not over, as companies worried about their treatment there are likely to appeal an order that kept alive the possibility for even bigger verdicts. (Source: Forbes.com Healthcare News)
Source: Forbes.com Healthcare News - May 2, 2018 Category: Pharmaceuticals Authors: Legal Newsline, Contributor Source Type: news

Samuel Epstein Leaves Legacy of Cancer Prevention
Dr. Samuel Epstein spent his life advocating cancer prevention and fighting against industries that put workers and consumers at risk. For more than 50 years, Epstein raised awareness of preventable causes of cancer. Among his targets was asbestos, a naturally occurring mineral linked to mesothelioma, lung cancer and other deadly conditions. He’s credited for saying the asbestos industry “successfully suppressed and manipulated information on the carcinogenicity and other hazards of asbestos.” In his 1998 book “The Politics of Cancer Revisited,” Epstein discussed the elaborate cover-up that Jo...
Source: Asbestos and Mesothelioma News - May 2, 2018 Category: Environmental Health Authors: Daniel King Source Type: news

Researchers Test Aerosol Chemotherapy for Mesothelioma
Chemotherapy can be given in a variety of ways. Now European researchers have added another method to the list for patients with peritoneal mesothelioma: Aerosol chemotherapy sprayed into the belly. A recent study reported outcomes for 24 patients who underwent the novel procedure. Pressurized intraperitoneal aerosol chemotherapy, or PIPAC, shrunk tumors and relieved symptoms in more than half of patients. The study was published in the April edition of BMC Cancer. The researchers believe aerosol chemotherapy can target abdominal cancer better than liquid chemotherapy. PIPAC is not yet available in the U.S., where docto...
Source: Asbestos and Mesothelioma News - April 30, 2018 Category: Environmental Health Authors: Daniel King Source Type: news

Blog: Today we reaffirm our demand for safe and healthy work for all
Today, UNISON is once again joining people around the world to mark International Workers’ Memorial Day. In doing so, we remember the dead and the injured, and recommit to continue the fight for the living, by reaffirming our demand for safe and healthy work for all. No-one goes to work not expecting to return home that day, yet official figures show that at least 20,000 workers die each year from work-related injuries and illnesses. The National Hazards Campaign believes that these official statistics are wildly inaccurate so the true figure is likely closer to 50,000 worker deaths every year. And this has even wide...
Source: UNISON meat hygiene - April 28, 2018 Category: Food Science Authors: Dave Prentis Tags: General secretary's blog News IWMD Source Type: news

Multimodal Treatment for Mesothelioma Shows Survival Benefit
This study confirmed, by comparison, the effectiveness of multimodal treatment,” Hassan said. “But you can’t rely [on] what you see in papers. Before choosing, patients have to talk with the oncologist, the surgeon, the pulmonologist, about benefits and risks of treatment.” Benefits of Nintedanib Discussed A second research group at ELCC presented on the benefits of the drug nintedanib in combination with chemotherapy for patients with mesothelioma. The report was part of a phase III clinical trial. Nintedanib, which is marketed as Ofev or Vargatef, is a small-molecule enzyme inhibitor which has sho...
Source: Asbestos and Mesothelioma News - April 27, 2018 Category: Environmental Health Authors: Daniel King Source Type: news

New Tool Determines If Vermiculite Insulation Contains Asbestos
Scientists with the United States Geology Survey (USGS) have created a hand-held spectrometer to determine if vermiculite insulation contains deadly amphibole asbestos. The recent innovation should provide a time-saving technique for commercial and home inspectors. Currently, inspectors must send samples to off-site laboratories before making that determination. “The emphasis was coming up with a method that was both reliable and easier to use,” Gregg Swayze, USGS scientist and lead researcher, told Asbestos.com. “We achieved that goal.” The findings were published in the April 2 edition of America...
Source: Asbestos and Mesothelioma News - April 24, 2018 Category: Environmental Health Authors: Matt Mauney Source Type: news

Yale Alumni Push Back Against Asbestos Tycoon Stephan Schmidheiny
Yale University alumni are pushing again to revoke the honorary degree given to Swiss billionaire Stephan Ernst Schmidheiny, whose asbestos-filled factories in Italy were responsible for the deaths of more than 2,000 people. Schmidheiny, 70, was sentenced to 16 years in prison and fined $15 billion in 2012 by an Italian court that found him negligent in protecting employees and nearby residents from deadly asbestos-related diseases such as mesothelioma. Schmidheiny received his honorary degree from Yale in 1996. In 2014, the university dismissed efforts by the Italy-based Asbestos Victims and Relatives Association and seve...
Source: Asbestos and Mesothelioma News - April 19, 2018 Category: Environmental Health Authors: Daniel King Source Type: news

Latest Mesothelioma Immunotherapy Combination Looks Promising
Scientists at the Vaccine and Immunotherapy Center (VIC) at Massachusetts General Hospital have uncovered a novel, two-agent immunotherapy combination that worked surprisingly well in animal models with malignant mesothelioma. The discovery has sparked new optimism for immunotherapy, which has struggled to provide consistently positive results with aggressive cancers such as mesothelioma. “This is the beginning of a new story of hope, a new combination of immunotherapy,” Dr. Mark Poznansky, director of the VIC and associate professor at Harvard Medical School, told Asbestos.com. “It worked quite well in a...
Source: Asbestos and Mesothelioma News - April 17, 2018 Category: Environmental Health Authors: Daniel King Source Type: news

Novocure touts top-line data from Ph2 mesothelioma trial
Novocure (NSDQ:NVCR) today touted positive top-line data from its Phase II pilot mesothelioma trial and revealed that it plans to submit a humanitarian device exemption application to the FDA for approval. The St. Helier, N.J.-based company reported that patients who received treatment with its “Tumor Treating Fields” system plus chemotherapy experienced clinically meaningful improvements in overall survival and progression-free survival compared to historical control data. Get the full story at our sister site, Drug Delivery Business News. The post Novocure touts top-line data from Ph2 mesothelioma trial ...
Source: Mass Device - April 17, 2018 Category: Medical Devices Authors: Sarah Faulkner Tags: Clinical Trials Drug-Device Combinations Pharmaceuticals Wall Street Beat NovoCure Source Type: news

Pleurectomy and Decortication the ‘ Way to Go ’ for Mesothelioma
Dr. Pietro Bertoglio and his colleagues at the University Hospital of Pisa stopped performing the aggressive extrapleural pneumonectomy (EPP) surgery for mesothelioma more than a decade ago. They believe it’s long overdue for everyone else to do the same and instead use the less-debilitating pleurectomy/decortication (P/D) procedure. The Journal of Thoracic and Cardiovascular Surgery recently published the University Hospital of Pisa’s 10-year experience using P/D and hyperthermic intrathoracic chemotherapy (HITHOC). Two editorial commentaries from thoracic surgeons in the U.S. accompanied the study from Italy,...
Source: Asbestos and Mesothelioma News - April 16, 2018 Category: Environmental Health Authors: Daniel King Source Type: news

J & J Baby Powder litigation takes new focus with asbestos claims
NEW YORK (Reuters) - A $117 million verdict against Johnson& Johnson and a supplier in favor of a man who said his asbestos-related cancer was caused by long-term use of J&J's Baby Powder could open a new front for thousands of cases claiming the widely-used product caused cancer, legal experts and plaintiffs lawyers said. (Source: Reuters: Health)
Source: Reuters: Health - April 16, 2018 Category: Consumer Health News Tags: healthNews Source Type: news

Man wins another $80m in Johnson & Johnson talcum powder case
Stephen Lanzo, 46, a man from Verona, New Jersey, who sued Johnson& Johnson claiming that baby powder gave him mesothelioma, has been awarded another $80 million in damages. (Source: the Mail online | Health)
Source: the Mail online | Health - April 11, 2018 Category: Consumer Health News Source Type: news

Man who got cancer from talcum powder wins another $80 MILLION in Johnson & Johnson case
Stephen Lanzo, 46, a man from Verona, New Jersey, who sued Johnson& Johnson claiming that baby powder gave him mesothelioma, has been awarded another $80 million in damages. (Source: the Mail online | Health)
Source: the Mail online | Health - April 11, 2018 Category: Consumer Health News Source Type: news